Response Evaluation Criteria in Solid Tumors (RECIST)

Response assessment	RECIST guideline, version 1.0^[1]	RECIST guideline, version 1.1^[2]
Target lesions
CR	Disappearance of all target lesions	Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to ≤10 mm
PR	≥30% decrease in the sum of the longest diameter of the target lesions compared with baseline	≥30% decrease in the sum of the longest diameter of the target lesions compared with baseline
PD	≥20% increase in the sum of the longest diameter of the target lesions compared with the smallest sum of the longest diameter recorded since treatment started OR The appearance of 1 or more new lesions	≥20% increase of at least 5 mm in the sum of the longest diameter of the target lesions compared with the smallest sum of the longest diameter recorded OR The appearance of new lesions, including those detected by FDG-PET
SD	Neither PR nor PD	Neither PR nor PD
Non-target lesions
CR	Disappearance of all non-target lesions and normalization of tumor marker levels	Disappearance of all non-target lesions and normalization of tumor marker levels
IR, SD	Persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits	Persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits
PD	Appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions	The appearance of 1 or more new lesions or unequivocal progression If patient has measurable disease, an increase in the overall level or substantial worsening in non-target lesions, such that tumor burden has increased, even if there is SD or PR in target lesions If no measurable disease, an increase in the overall tumor burden comparable in magnitude with the increase that would be required to declare PD in measurable disease (eg, an increase in pleural effusions from trace to large, or an increase in lymphangitic disease from localized to widespread)

CR: complete response; PR: partial response; PD: progressive disease; FDG-PET: fludeoxyglucose positron emission tomography; SD: stable disease; IR: incomplete response.

References:

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.
Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.

Graphic 74693 Version 13.0

خرید پکیج

Response Evaluation Criteria in Solid Tumors (RECIST)